Skip to content Skip to footer
Subscribe Now
Life Sciences Deals Top 20 2021
TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B. This article is based on the 2021…
February 10, 2022

Read more

Viewpoints_Dennis Williams
VIEWPOINTS

PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market

In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform and their pathway to bringing the first-ever TCR T-cell therapy for solid tumors to market along with an overview about their industry-leading T-cell therapy pipeline in solid tumors.…
August 16, 2021

Read more